Skip to main content

Table 1 Demographic and clinical characteristics of the two groups

From: Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial

Variable

Control group (N = 104)

HPV vaccine group (N = 138)

P value

Age, (y)

 Min- Max

22–41

22–42

 

 Mean ± SD

33.04 ± 4.6

31.7 ± 4.8

0.5*

Marital status; N (%)

 Married

103 (99)

136 (98.5)

 

 Divorced

1 (1)

2 (1.45)

0.8**

CIN 1; N (%)

35 (33.7)

45 (32.6)

 

CIN 2; N (%)

35 (33.7)

50 (36.2)

0.3***

CIN 3; N (%)

34 (32.6)

43 (31.2)

 

Two-dose vaccination; N (%)

–

35 (26.4)

–

Three-dose vaccination; N (%)

–

103 (74.6)

 
  1. Abbreviations: Y year; N number; CIN Cervical intraepithelial neoplasia; SD Standard deviation, *Student’s t test, ** Fisher’s exact test, ***Chi-squared test